[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-338864-105":59,"doc-detail-338864-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","integrating-clinical-cancer-and-ptm-proteomics-data-identifies-a-mechanism-of-ack1-kinase-activation","Integrating Clinical Cancer and PTM Proteomics Data Identiﬁes a Mechanism of ACK1 Kinase Activation","","Machine learning identifies low-frequency oncogenic mut-drivers by integrating curated clinical cancer records with posttranslational modification (PTM) proteomics databases. The model was trained and applied to 62,746 patient cancers across 84 cancer types, predicting 3,964 oncogenic mutations spanning 1,148 genes, including mutations that disrupt PTMs of both known and unknown function. The tool is deployed as a web application and demonstrated on nonreceptor tyrosine kinases (NRTKs).",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/integrating-clinical-cancer-and-ptm-proteomics-data-identifies-a-mechanism-of-ack1-kinase-activation/338864/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/integrating-clinical-cancer-and-ptm-proteomics-data-identifies-a-mechanism-of-ack1-kinase-activation/338864.png","ImageObject",300,407,{"name":92,"@type":93},"Logic","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What data sources does the machine learning model integrate to find mut-drivers?","Question",{"text":112,"@type":113},"It integrates curated clinical cancer data with posttranslational modification (PTM) proteomics databases.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was the approach validated across patient cancers?",{"text":117,"@type":113},"The study applied the model to 62,746 patient cancers spanning 84 cancer types and predicted 3,964 oncogenic mutations across 1,148 genes.",{"name":119,"@type":110,"acceptedAnswer":120},"What mechanism does the case study reveal for ACK1 kinase activation?",{"text":121,"@type":113},"A recurrent ACK1 mutation disrupts the Mig6 homology region (MHR) and ubiquitin-association (UBA) domains, where MHR disruption promotes kinase activation and UBA disruption increases stability by blocking lysosomal degradation.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},338864,1790143412,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1099513958762,"https://ap-avatar.wpscdn.com/avatar/1000023916a998db790?x-image-process=image/resize,m_fixed,w_180,h_180&k=1784791008015729253","Integrating Clinical Cancer and PTM Proteomics Data Identiﬁes a Mechanism of ACK1 Kinase Activation  \nEranga R. Balasooriya1,2,3, Deshan Madhusanka1,4, Tania P. Lpez-Palacios1,4, Riley J. Eastmond1, Dasun Jayatunge1,4, Jake J. Owen1, Jack S. Gashler1, Christina M. Egbert1, Chanaka Bulathsinghalage5, Lu Liu5, Stephen R. Piccolo6, and Joshua L. Andersen1,4  \nABSTRACT  \n◥  \nBeyond the most common oncogenes activated by mutation (mut-drivers), there likely exists a variety of low-frequency mutdrivers, each of which is a possible frontier for targeted therapy. To identify new and understudied mut-drivers, we developed a machine learning (ML) model that integrates curated clinical cancer data and posttranslational modiﬁcation (PTM) proteomics databases. We applied the approach to 62,746 patient cancers spanning 84 cancer types and predicted 3,964 oncogenic mutations across 1,148 genes, many of which disrupt PTMs of known and unknown function. The list of putative mut-drivers includes established drivers and others with poorly understood roles in cancer. This ML model is available as a web application. As a case study, we focused the approach on nonreceptor tyrosine kinases (NRTK) and found a recurrent mutation in activated CDC42 kinase-1 (ACK1) that disrupts the Mig6  \nhomology region (MHR) and ubiquitin-association (UBA) domains on the ACK1 C-terminus. By studying these domainsin cultured cells, we found that disruption of the MHR domain helps activate the kinase while disruption of the UBA increases kinase stability by blocking its lysosomal degradation. This ACK1 mutation is analogous to lymphoma-associated mutations in its sister kinase, TNK1, which also disrupt a C-terminal inhibitory motif and UBA domain. This study establishes amut-driver discovery tool for the research community and identiﬁes a mechanism of ACK1 hyperactivation shared among ACK family kinases.  \nImplications: This research identiﬁes a potentially targetable activating mutation in ACK1 and other possible oncogenic mutations, including PTM-disrupting mutations, for further study.  \nIntroduction  \nDecades of research have uncovered a relatively limited number of genes that, when aberrantly activated by mutation, promote tumorigenesis (1). These genes, referred to here as oncogenic “mut-drivers,”include HER2 (􀀁 14% of breast cancer), KRAS (􀀁 30% of lung adenocarcinoma), and BCR-ABL (deﬁning lesion of chronic myeloid leukemia) . Although these and other well-described mut-drivers occupy a large fraction of the oncogene landscape, a variety of lowfrequency mut-drivers likely exist but may bedifﬁcult to detect because they fail to rise signiﬁcantly above the noise in genomics data, occur only in combination with other mut-drivers, or are speciﬁc toa cancer type or subtype (1) . Recent examples of low-frequency mut-drivers currently targeted in the clinic include fusion kinases such as ROS1 and NTRK, in which activating mutations occur  \n1The Fritz B. Burns Cancer Research Laboratory, Department of Chemistry and Biochemistry, Brigham Young University, Provo, Utah. 2Center for Cancer Research, Massachusetts General Hospital, Boston, Massachusetts. 3Dept. of Medicine, Harvard Medical School, Boston, Massachusetts. 4Department of Oncological Sciences and Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, Utah. 5Department of Computer Science, North Dakota State University, Fargo, North Dakota. 6Department of Biology, Brigham Young University, Provo, Utah.  \nCorresponding Author: Joshua L. Andersen, Huntsman Cancer Institute, 2000 Circle of Hope, Room 5262, Salt Lake City, UT 84112 . E-mail:  \n[josh.andersen@hci.utah.edu](josh.andersen@hci.utah.edu)[ ](josh.andersen@hci.utah.edu)[Mol Cancer Res 2024](Mol Cancer Res 2024);[22:137](22:137)–[51](51)  \n[doi:](doi: 10.1158/1541-7786.MCR-23-0153)[ 10.1158/1541-7786.MCR-23-0153](doi: 10.1158/1541-7786.MCR-23-0153)  \nThis open access article is distributed under the Creative Commons AttributionNon","cbCaiurJxDr8dqVi","https://ap.wps.com/l/cbCaiurJxDr8dqVi","pdf",11235309,15,"English","# Abstract\n# Implications\n# Introduction","[{\"question\":\"What data sources does the machine learning model integrate to find mut-drivers?\",\"answer\":\"It integrates curated clinical cancer data with posttranslational modification (PTM) proteomics databases.\"},{\"question\":\"How was the approach validated across patient cancers?\",\"answer\":\"The study applied the model to 62,746 patient cancers spanning 84 cancer types and predicted 3,964 oncogenic mutations across 1,148 genes.\"},{\"question\":\"What mechanism does the case study reveal for ACK1 kinase activation?\",\"answer\":\"A recurrent ACK1 mutation disrupts the Mig6 homology region (MHR) and ubiquitin-association (UBA) domains, where MHR disruption promotes kinase activation and UBA disruption increases stability by blocking lysosomal degradation.\"}]","Integrating Clinical Cancer and PTM Proteomics Data Identiﬁes a Mechanism of ACK1 Kinase Activation | PDF",1790026278,38,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c586542dc37b817c29dd0937f9b4621a.webp",983,1286,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c39da9cb9ef0feab02e8c4a1040afa14.webp",982,1285,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/40d2321f1e95370721b975627fc997ea.webp",981,1283,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fb2e06f4c90f6270958ed9ff52d94acf.webp",980,1282]